Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words 'Giles, FJ' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 73 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Dabaja, BS; O'Brien, SM; Kantarjian, HM; Cortes, JE; Thomas, DA; Albitar, M; Schlette, ES; Faderl, S; Sarris, A; Keating, MJ; Giles, FJ
      Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoxome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome

      LEUKEMIA & LYMPHOMA
    2. Verstovsek, S; Estey, E; Manshouri, T; Keating, M; Kantarjian, H; Giles, FJ; Albitar, M
      High expression of the receptor tyrosine kinase Tie-1 in acute myeloid leukemia and myelodysplastic syndrome

      LEUKEMIA & LYMPHOMA
    3. Giles, FJ; Shen, Y; Kantarjian, HM; Korbling, MJ; O'Brien, S; Anderlini, P; Donato, M; Pierce, S; Keating, MJ; Freireich, EJ; Estey, E
      Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long term survival

      LEUKEMIA & LYMPHOMA
    4. Giles, FJ; Kantarjian, H; O'Brien, S; Rios, MB; Cortes, J; Beran, M; Koller, C; Keating, M; Talpaz, M
      Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with Philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase

      LEUKEMIA & LYMPHOMA
    5. Beck, JR; Guilhot, J; Giles, FJ; Aoki, N; Wirt, DP; Guilhot, F
      Cytarabine added to interferon improves the cost-effectiveness of initial therapy for patients with early chronic phase chronic myelogenous leukemia

      LEUKEMIA & LYMPHOMA
    6. Wirt, DP; Giles, FJ; Oken, MM; Solal-Celigny, P; Beck, JR
      Cost-effectiveness of interferon alfa-2b added to chemotherapy for high-tumor-burden follicular non-Hodgkin's lymphoma

      LEUKEMIA & LYMPHOMA
    7. Verstovsek, S; Kantarjian, H; Estey, E; Aguayo, A; Giles, FJ; Manshouri, T; Koller, C; Estrov, Z; Freireich, E; Keating, M; Albitar, M
      Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome

      LEUKEMIA
    8. Verstovsek, S; Manshouri, T; Kantarjian, H; Giles, FJ; Keating, M; Estey, E; Albitar, M
      Highly reproducible detection and semi-quantification of telomerase activity

      BIOTECHNIQUES
    9. O'Brien, SM; Kantarjian, H; Thomas, DA; Giles, FJ; Freireich, EJ; Cortes, J; Lerner, S; Keating, MJ
      Rituximab dose-escalation trial in chronic lymphocytic leukemia

      JOURNAL OF CLINICAL ONCOLOGY
    10. O'Brien, SM; Kantarjian, AM; Cortes, J; Beran, M; Koller, CA; Giles, FJ; Lerner, S; Keating, M
      Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia

      JOURNAL OF CLINICAL ONCOLOGY
    11. Giles, FJ; Cortes, JE; Baker, SD; Thomas, DA; O'Brien, S; Smith, TL; Beran, M; Bivins, C; Jolivet, J; Kantarjian, HM
      Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia

      JOURNAL OF CLINICAL ONCOLOGY
    12. Beran, M; Shen, Y; Kantarjian, H; O'Brien, S; Koller, CA; Giles, FJ; Cortes, J; Thomas, DA; Faderl, S; Despa, S; Estey, EH
      High-dose chemotherapy in high-risk myelodysplastic syndrome - Covariate-adjusted comparison of five regimens

      CANCER
    13. Giles, FJ; Kantarjian, HM; Kornblau, SM; Thomas, DA; Garcia-Manero, G; Waddelow, TA; David, CL; Phan, AT; Colburn, DE; Rashid, A; Estey, EH
      Mylotarg(TM) (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

      CANCER
    14. Kantarjian, HM; Shan, JQ; Smith, T; Talpaz, M; Kozuch, P; Rios, MB; Cortes, J; Giles, FJ; O'Brien, S
      Response to therapy is independently associated with survival prolongationin chronic myelogenous leukemia in the blastic phase

      CANCER
    15. Ravandi, F; Kantarjian, HM; Talpaz, M; O'Brien, S; Faderl, S; Giles, FJ; Thomas, D; Cortes, J; Andreeff, M; Estrov, Z; Rios, MB; Albitar, M
      Expression of apoptosis proteins in chronic myelogenous leukemia - Associations and significance

      CANCER
    16. Talpaz, M; O'Brien, S; Rose, E; Gupta, S; Shan, JQ; Cortes, J; Giles, FJ; Faderl, S; Kantarjian, HM
      Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia

      BLOOD
    17. Estey, EH; Thall, PF; Cortes, JE; Giles, FJ; O'Brien, S; Pierce, SA; Wang, XM; Kantarjian, HM; Beran, M
      Comparison of idarubicin plus ara-C-, fludarabine plus ara-C-, and topotecan plus ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts

      BLOOD
    18. Smolich, BD; Yuen, HA; West, KA; Giles, FJ; Albitar, M; Cherrington, JM
      The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit theSCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts

      BLOOD
    19. Vey, N; Giles, FJ; Kantarjian, H; Smith, TL; Beran, M; Jeha, S
      The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia

      CLINICAL CANCER RESEARCH
    20. Giles, FJ; Shan, JQ; Advani, SH; Akan, H; Aydogdu, I; Aziz, Z; Azim, HA; Bapsy, PP; Buyukkececi, F; Chaimongkol, B; Chen, PM; Cheong, SK; Ferhanoglu, B; Hamza, R; Khalid, HM; Intragumtornchai, T; Kim, SW; Kim, SY; Koc, H; Kumar, L; Kumar, R; Lei, KI; Lekhakula, A; Muthalib, A; Patel, M; Poovalingam, VP; Prayoonwiwat, W; Rana, F; Reksodiputro, AH; Ruff, P; Sagar, TG; Schwarer, AP; Song, HS; Suh, CW; Suharti, C; Supindiman, I; Tee, GY; Thamprasit, T; Villalon, AH; Wickham, NR; Wong, JE; Yalcin, A; Jootar, S
      A prospective randomized study of CHOP versus CHOP plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: The International Oncology Study Group NHL1 study

      LEUKEMIA & LYMPHOMA
    21. Giles, FJ; Shan, JQ; Chen, SS; Advani, SH; Supandiman, I; Aziz, Z; Caviles, AP; Tee, GY; Chasen, MR; Fahed, Z; Chao, TY; Aydogdu, I; Lynott, AM
      A prospective randomized study of alpha-2b interferon plus hydroxyurea or cytarabine for patients with early chronic phase chronic myelogenous leukemia: The International Oncology Study Group CML1 study

      LEUKEMIA & LYMPHOMA
    22. Giles, FJ; Wong, GC; Clark, SJ; Pierce, S; Kantarjian, HM; Keating, MJ
      Oral idarubicin in patients with late chronic phase chronic myelogenous leukemia or chronic myelomonocytic leukemia

      LEUKEMIA & LYMPHOMA
    23. Ravandi-Kashani, F; Cortes, J; Giles, FJ
      Myelodysplasia presenting as granulocytic sarcoma of mediastinum causing superior vena cava syndrome

      LEUKEMIA & LYMPHOMA
    24. Kantarjian, HM; O'Brien, S; Smith, TL; Cortes, J; Giles, FJ; Beran, M; Pierce, S; Huh, Y; Andreeff, M; Koller, C; Ha, CS; Keating, MJ; Murphy, S; Freireich, EJ
      Results of treatment with Hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia

      JOURNAL OF CLINICAL ONCOLOGY
    25. Kantarjian, HM; Talpaz, M; Smith, TL; Cortes, J; Giles, FJ; Rios, MB; Mallard, S; Gajewski, A; Murgo, A; Cheson, B; O'Brien, S
      Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia

      JOURNAL OF CLINICAL ONCOLOGY
    26. Giles, FJ; Wickham, NR; Rapoport, BL; Somlo, G; Lim, SW; Shan, JQ; Lynott, AM
      Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: An International Oncology Study Group (IOSG) Phase II protocol

      AMERICAN JOURNAL OF HEMATOLOGY
    27. Kantarjian, HM; Giles, FJ; O'Brien, S
      Therapeutic choices in younger patients with chronic myelogenous leukemia

      CANCER
    28. Kaban, K; Kantarjian, H; Talpaz, M; O'Brien, S; Cortes, J; Giles, FJ; Pierce, S; Albitar, M
      Expression of thrombopoietin and its receptor (c-mpl) in chronic myelogenous leukemia - Correlation with disease progression and response to therapy

      CANCER
    29. Giles, FJ; Keating, AR; Kurzrock, R; Talpaz, M
      A pilot study of recombinant human interleukin-4 therapy of myelofibrosis

      JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
    30. Giles, FJ; O'Brien, SM; Santini, V; Gandhi, V; Plunkett, W; Seymour, JF; Robertson, LE; Kantarjian, HM; Keating, MJ
      Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: A phase II study

      LEUKEMIA & LYMPHOMA
    31. Sacchi, S; Kantarjian, HM; Freireich, EJ; O'Brien, SO; Cortes, J; Rios, MB; Kornblau, S; Giles, FJ; Koller, C; Gajewski, J; Talpaz, M
      Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia

      LEUKEMIA & LYMPHOMA
    32. Beran, M; Estey, E; O'Brien, S; Cortes, J; Koller, CA; Giles, FJ; Kornblau, S; Andreeff, M; Vey, N; Pierce, SR; Hayes, K; Wong, GC; Keating, M; Kantarjian, H
      Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia

      JOURNAL OF CLINICAL ONCOLOGY
    33. Kantarjian, HM; O'Brien, S; Smith, TL; Rios, MB; Cortes, J; Beran, M; Koller, C; Giles, FJ; Andreeff, M; Kornblau, S; Giralt, S; Keating, MJ; Talpaz, M
      Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine

      JOURNAL OF CLINICAL ONCOLOGY
    34. Santini, V; Giles, FJ
      The potential of amifostine: from cytoprotectant to therapeutic agent

      HAEMATOLOGICA
    35. Ravandi-Kashani, F; Estey, E; Cortes, J; Medeiros, LJ; Giles, FJ
      Granulocytic sarcoma of the pancreas: a report of two cases and literaturereview

      CLINICAL AND LABORATORY HAEMATOLOGY
    36. Thomas, DA; Kantarjian, H; Smith, TL; Koller, C; Cortes, J; O'Brien, S; Giles, FJ; Gajewski, J; Pierce, S; Keating, MJ
      Primary refractory and relapsed adult acute lymphoblastic leukemia - Characteristics, treatment results, and prognosis with salvage therapy

      CANCER
    37. Giles, FJ; Kantarjian, HM; Cortes, J; Thomas, DA; Talpaz, M; Manshouri, T; Albitar, M
      Multidrug resistance protein expression in chronic myeloid leukemia - Associations and significance

      CANCER
    38. Sacchi, S; Kantarjian, HM; O'Brien, S; Cortes, J; Rios, MB; Giles, FJ; Beran, M; Koller, CA; Keating, MJ; Talpaz, M
      Chronic myelogenous leukemia in nonlymphoid blastic phase - Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients

      CANCER
    39. Estey, EH; Giles, FJ; Kantarjian, H; O'Brien, S; Cortes, J; Freireich, EJ; Lopez-Berestein, G; Keating, M
      Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia

      BLOOD
    40. GILES FJ
      MONOCYTE-MACROPHAGES, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR, AND PROLONGED SURVIVAL AMONG PATIENTS WITH ACUTE MYELOID-LEUKEMIA AND STEM-CELL TRANSPLANTS

      Clinical infectious diseases
    41. Beran, M; Estey, E; O'Brien, SM; Giles, FJ; Koller, CA; Kornblau, S; Keating, M; Kantarjian, HM
      Results of topotecan single-agent therapy in patients with myelodysplasticsyndromes and chronic myelomonocytic leukemia

      LEUKEMIA & LYMPHOMA
    42. KANTARJIAN HM; GILES FJ; OBRIEN SM; TALPAZ M
      CLINICAL COURSE AND THERAPY OF CHRONIC MYELOGENOUS LEUKEMIA WITH INTERFERON-ALPHA AND CHEMOTHERAPY

      Hematology/oncology clinics of North America
    43. GILES FJ; KANEMAKI TJ; SCHRECK RR; QASABIAN L; FUERST MP; LIM SW
      TRANSLOCATION (3-21-8)(Q21-Q22-Q22) IN A PATIENT WITH ACUTE MYELOID-LEUKEMIA - A CASE-REPORT AND REVIEW OF PROGNOSTIC INDICATORS

      Cancer genetics and cytogenetics
    44. GILES FJ; OBRIEN SM; KEATING MJ
      CHRONIC LYMPHOCYTIC-LEUKEMIA IN (RICHTERS) TRANSFORMATION

      Seminars in oncology
    45. GILES FJ; SHAH PM; TEE GY; WANG LX; CAVILEZ A; SUPANDIMAN I; RANA F; RAPOPORT BL; FAHED Z; AZIZ Z; SUHARTI C; CHEN YC; TAN P; SALIM KA; KOCHUPILLAI V; GONZAGA M; ALI NM; ADVANI SH; PATEL M; CHEN S; TORRES R; TAM J; LYNOTT AM; LIM SW; FUERST MP; KUSUANCO DA; POOVALINGAM V
      ADVERSE-EFFECTS OF ALPHA-2B INTERFERON (IFN) IN PATIENTS WITH PH-PHASE CHRONIC MYELOGENOUS LEUKEMIA ENROLLED IN THE INTERNATIONAL ONCOLOGY STUDY-GROUP (IOSG) CML1 STUDY( EARLY CHRONIC)

      British Journal of Haematology
    46. GILES FJ; KUSUANCO D; LYNOTT A; SHAH PM; WANG LX; SUPANDIMAN I; POOVALINGAM V; RANA F; AZIZ F; CHEN YC; DUTOIT PJ; JANUSZEWICZ H; TEE GY; WOLF M; SUMANTRI R; ALOMARI K; TIAN D; BEZWODA WR; ABDI E; GONZAGA M; FAHED F; FOURIE LS; RUFF P; POOL R; KIM HC; PARIKH PM; KIM KY; HO BS; TAN P; LEE SN; TIEN SL; WIJONO A; LOBERIZA S; LEE GH; KIM SY; HO CH; BAYLON H; AHN MJ; THOMAS M; WOLF M; TIEN HF; AYDOGDU I; TAM J; LIM SW; CAVILEZ A
      PROGNOSTIC FACTORS IN PATIENTS WITH PH-PHASE CHRONIC MYELOGENOUS LEUKEMIA (CML) ENROLLED IN THE INTERNATIONAL ONCOLOGY STUDY-GROUP (IOSG) CML1 STUDY( EARLY CHRONIC)

      British Journal of Haematology
    47. JEWELL AP; WORMAN CP; GILES FJ; GOLDSTONE AH
      SERUM LEVELS OF TNF, IL-6 AND SCD23 CORRELATE WITH CHANGES IN LYMPHOCYTE COUNT IN PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC-LEUKEMIA RECEIVING INTERFERON-ALPHA THERAPY

      Leukemia & lymphoma
    48. GILES FJ; WAXMAN AD; NGUYEN KN; FUERST MP; KUSUANCO DA; FRANCO MM; BIERMAN H; LIM SW
      COMPARISON OF TC-99M SESTAMIBI AND IN-111 OCTREOTIDE IMAGING IN A PATIENT WITH EWINGS-SARCOMA BEFORE AND AFTER STEM-CELL TRANSPLANTATION

      Cancer
    49. WIRT DP; GILES FJ; OKEN MM; SOLALCELIGNY P; BECK JR
      COST-EFFECTIVENESS OF INTERFERON-ALPHA ADDED TO CHEMOTHERAPY FOR HIGHTUMOR BURDEN FOLLICULAR NON-HODGKINS-LYMPHOMA

      Blood
    50. JEWELL AP; GILES FJ
      CUTANEOUS MANIFESTATION OF LEISHMANIASIS 40 YEARS AFTER EXPOSURE IN APATIENT WITH CHRONIC LYMPHOCYTIC-LEUKEMIA

      Leukemia & lymphoma
    51. LOOK RM; LIM SW; WAXMAN AD; GUPTA PK; FUERST MMP; KUSUANCO DA; LAWRENCE GN; GILES FJ
      TC-99M SESTAMIBI SCANNING IN MULTIPLE-MYELOMA STEM-CELL TRANSPLANTATION

      Leukemia & lymphoma
    52. LIM SW; FALK RE; LOOK RM; FUERST MM; LAWRENCE GN; KUSUANCO DA; GILES FJ
      TRANSLOCATION (12-15)(P13-Q13) IN A PATIENT WITH RELAPSED ACUTE MYELOID-LEUKEMIA

      Cancer genetics and cytogenetics
    53. GILES FJ; LIM SW; VILLALON A; BAPSY PP; CHAIMONGKOL B; RAAFAT J; JOOTAR S; ISMAIL K; KHALID H; ADNAN AF; HASHEM T; FRANCO MM
      COMPARISON OF HISTOLOGIC DISTRIBUTION END EXTRANODAL INVOLVEMENT IN INTERMEDIATE AND HIGH-GRADE NON-HODGKINS-LYMPHOMA IN ASIAN, EGYPTIAN, AND US PATIENT COHORTS

      Blood
    54. GILES FJ; AVVISATI G; SUPANDIMAN I; WICKHAM NR; SUH C; SUHARTI C; MUTHALIB A; TAN P; LEE CH; KUCHOPILLAI V; HARRYANTO A; LEKHAKULA A; RAPOPORT BL; SAGAR TG; AKAN H; RAAFAT J; USKENT N; PARIKH PM; SALIM KA; RADHESHYAM D; RUFF P; HO CH; CHEN YC; SUWANSELA N; KANG JH; SMRUTI BK; PATEL M; KIM SY; TIAN D; THAMPRASIT T; LEE KB; GONZAGA M; SUMANTRI R; NARCISO C; WANG PN; CHASEN MR; RAATS JI; CHAO TY; ANGGRAENI E; RAGNUHARDI D; ONA N; GOPAL BK; COMIA S; FUERST MP; LIM SW; FRANCO MM; KUSUANCO DA
      COMPARISON OF INITIAL CLINICAL CHARACTERISTICS BETWEEN ASIAN AND ITALIAN MULTIPLE-MYELOMA (MM) PATIENTS ENTERING THE INTERNATIONAL ONCOLOGYSTUDY-GROUP (IOSG) MM1 AND THE ITALIAN MM STUDY-GROUP PROTOCOLS

      Blood
    55. GILES FJ; WICKHAM NR; RAPOPORT BL; FONG W; SOMLO G; FUERST MP; KUSUANCO DA; FRANCO MM; FISCHER DA; HUGHLETT CE; LIM SW
      CYCLOPHOSPHAMIDE, ETOPOSIDE, VINCRISTINE, ADRIAMYCIN AND DEXAMETHASONE (CEVAD) RGM-CSF IS AN EFFECTIVE REGIMEN IN REFRACTORY OR RELAPSED MULTIPLE-MYELOMA (MM)

      Blood
    56. GILES FJ; OBRIEN S; KANTARJIAN HM; PLUNKETT W; ESTEY E; BERAN M; YANG LY; SEYMOUR J; ROBERTSON LE; LERNER S; KEATING MJ
      SEQUENTIAL CISPLATINUM, FLUDARABINE, AND ARABINOSYL CYTOSINE (PFA) INPATIENTS WITH PRIOR FLUDARABINE THERAPY FOR CHRONIC LYMPHOCYTIC-LEUKEMIA (CLL) - A PHASE-II STUDY

      Blood
    57. GILES FJ; OBRIEN S; KANTARJIAN HM; ESTEY E; KOLLER C; PLUNKETT W; YANG LY; SEYMOUR J; ROBERTSON LE; LERNER S; KEATING MJ
      SEQUENTIAL CISPLATINUM, FLUDARABINE, AND ARABINOSYL CYTOSINE (PFA) ORCYCLOPHOSPHAMIDE, FLUDARABINE AND ARABINOSYL CYTOSINE (CFA) IN PATIENTS WITH RICHTERS-SYNDROME (RS) - A PILOT-STUDY

      Blood
    58. GILES FJ; LIM SW; KANEMAKI TJ; HAMBURG SI; TAM JT; HEIFETZ LJ; FRANCO MM; MCANDREW PF; DECKER RW; FUERST MMP; ROSENBLOOM BE; GREEN LM; ROSENFELT FP; LYMAN SD
      FLT3 LIGAND SERUM LEVELS IN PATIENTS RECEIVING CYTOTOXIC CHEMOTHERAPY

      Blood
    59. ELLIS GK; HUTCHINS L; JIMENEZMARTIN M; PECORA AL; BARNADAS A; MEISENBERG B; NABHOLTZ JM; CORTESFUNES H; RIFKIN R; CHANG AYC; GARRISON L; GEORGE C; GILES FJ
      PHASE-III DOUBLE-BLIND RANDOMIZED STUDY OF PIXY321 VERSUS GCSF AFTER CEP FOR BREAST OR OVARIAN-CARCINOMA

      Blood
    60. GILES FJ; KANEMAKI TJ; OTSUKI JT; PON DF; HEIFETZ LJ; MCANDREW PF; KOH HA; LIM SW
      SINGLE-AGENT CEFTAZIDIME (CTZ) VS MULTIPLE ANTIBIOTICS IN THE TREATMENT OF CHEMOTHERAPY-INDUCED NEUTROPENIC FEVER (NF) - IMPACT OF A CLINICAL PATHWAY IN ANTIBIOTIC UTILIZATION AND ANTIBIOTIC-RESISTANCE

      Blood
    61. KATTAN MW; INOUE Y; GILES FJ; TALPAZ M; OZER H; GUILHOT F; ZUFFA E; HUBER SL; BECK JR
      COST-EFFECTIVENESS OF INTERFERON-ALPHA AND CONVENTIONAL CHEMOTHERAPY IN CHRONIC MYELOGENOUS LEUKEMIA

      Annals of internal medicine
    62. GILES FJ
      CURRENT THERAPY OF REFRACTORY MULTIPLE-MYELOMA

      Stem cells
    63. JEWELL AP; LYDYARD PM; WORMAN CP; GILES FJ; GOLDSTONE AH
      GROWTH-FACTORS CAN PROTECT B-CHRONIC LYMPHOCYTIC-LEUKEMIA CELLS AGAINST PROGRAMMED CELL-DEATH WITHOUT STIMULATING PROLIFERATION

      Leukemia & lymphoma
    64. GILES FJ
      REFRACTORY MULTIPLE-MYELOMA - RECENT ADVANCES IN THERAPY

      Hematologic pathology
    65. LOOK RM; LIM SW; SCHRECK RR; LEE S; FUERST MP; LAWRENCE GN; KUSUANCO DA; KESSLER CE; GILES FJ
      BURKITT TRANSLOCATION (8-22)(Q24-Q11) IN A PATIENT WITH MULTIPLE-MYELOMA

      Cancer genetics and cytogenetics
    66. KOH HA; OTSUKI JT; PON DF; LOOK RM; HEIFETZ LJ; MCANDREW PF; ZAKOWSKI PC; GLICK MM; MORGAN MA; SHANE RR; LIM SW; GILES FJ
      SINGLE-AGENT CEFTAZIDIME (CTZ) VS MULTIPLE ANTIBIOTICS IN TREATMENT OF CHEMOTHERAPY-INDUCED NEUTROPENIC FEVER (NF) - IMPACT OF A CLINICAL PATHWAY

      Blood
    67. KOH HA; OTSUKI JT; LIM SW; DECKER RW; HAMBURG SI; LOOK RM; FUERST MP; LAWRENCE GN; KUSUANCO DA; GILES FJ
      ACUTE MYELOGENOUS LEUKEMIA (AML) IN THE ELDERLY - 6 YEARS EXPERIENCE IN AN ACADEMIC COMMUNITY-HOSPITAL

      Blood
    68. MCSWEENEY EN; GILES FJ; GOLDSTONE AH
      RECOMBINANT INTERFERON-ALPHA(2) ANTIBODIES IN CHRONIC LYMPHOCYTIC-LEUKEMIA

      Journal of interferon research
    69. JEWELL AP; WORMAN CP; LYDYARD PM; YONG KL; GILES FJ; GOLDSTONE AH
      INTERFERON-ALPHA UP-REGULATES BCL-2 EXPRESSION AND PROTECTS B-CLL CELLS FROM APOPTOSIS IN-VITRO AND IN-VIVO

      British Journal of Haematology
    70. JEWELL AP; YONG KL; WORMAN CP; TSAKONA CP; GILES FJ; GOLDSTONE AH
      SERUM MACROPHAGE-COLONY-STIMULATING FACTOR (M-CSF) LEVELS CORRELATE WITH CLINICAL-RESPONSE TO INTERFERON-ALPHA IN PATIENTS WITH EARLY-STAGEB-CLL

      British Journal of Haematology
    71. MCSWEENEY EN; GILES FJ; WORMAN CP; JEWEL AP; TSAKONA CP; HOFFBRAND AV; MEHTA AB; NEWLAND AC; CAWLEY JC; GALVANI D; SINGER CRJ; GRANT IR; NORFOLK DR; GOLDSTONE AH
      RECOMBINANT INTERFERON-ALFA 2A IN THE TREATMENT OF PATIENTS WITH EARLY STAGE-B CHRONIC LYMPHOCYTIC-LEUKEMIA

      British Journal of Haematology
    72. MCSWEENEY EN; GILES FJ; GRANT IR; GOLDSTONE AH
      ANTI-IFN ANTIBODIES IN PATIENTS WITH MYELOPROLIFERATIVE ASSOCIATED THROMBOCYTOSIS TREATED WITH ALFA IFN-ALPHA

      British Journal of Haematology
    73. JEWELL AP; WORMAN CP; GILES FJ; LYDYARD PM; GOLDSTONE AH
      CYTOKINE REGULATION OF APOPTOSIS OF B-CLL CELLS IN-VITRO

      Blood


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/05/20 alle ore 09:43:43